{"title":"FDA小组讨论SSRI风险标签；APA引起关注","authors":"Valerie A. Canady","doi":"10.1002/mhw.34565","DOIUrl":null,"url":null,"abstract":"<p>A recent Food and Drug Administration (FDA) expert panel meeting has reignited debate over the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, with discussions centering on whether to add a Black Box warning to these commonly prescribed antidepressants.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":"35 33","pages":"3-4"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FDA panel debates SSRI risk label; APA raises concerns\",\"authors\":\"Valerie A. Canady\",\"doi\":\"10.1002/mhw.34565\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A recent Food and Drug Administration (FDA) expert panel meeting has reignited debate over the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, with discussions centering on whether to add a Black Box warning to these commonly prescribed antidepressants.</p>\",\"PeriodicalId\":100916,\"journal\":{\"name\":\"Mental Health Weekly\",\"volume\":\"35 33\",\"pages\":\"3-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34565\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34565","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
FDA panel debates SSRI risk label; APA raises concerns
A recent Food and Drug Administration (FDA) expert panel meeting has reignited debate over the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, with discussions centering on whether to add a Black Box warning to these commonly prescribed antidepressants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
